MedCity News August 30, 2023
Maximillian Vargas and Caitlin Verrilli

Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.

The Inflation Reduction Act was created and passed to reduce patient and government burden in paying for expensive drugs. While the new legislation is intended to provide Medicare patients with better access to the treatments they need, certain provisions have the effect of penalizing research and driving companies away from developing specific types of drugs—in particular, potential treatments for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article